Bristol Myers Squibb engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals.
Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals, and Nutritionals. The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Feb 21, 2017 | Post-IPO Equity | $80M | 2 | — | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Nov 29, 2022
Cajal Neuroscience
|
Series A | $96M | Biotechnology | — |
Jul 20, 2022
BigHat Biosciences
|
Series B | $75M | Artificial Intelligence | — |
Jun 8, 2022
Owkin
|
Series B | $50M | Artificial Intelligence | Yes |
Jan 25, 2022
Metagenomi
|
Series B | $175M | Artificial Intelligence | — |
May 1, 2012
Pindrop
|
Seed | $1M | Audio | — |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Litmore Capital | — | Post-IPO Equity |
Knoll Capital Management | — | Post-IPO Equity |